Pharmacogenomics (PGx)

P-007 - THE FREQUENCY OF MAJOR GENETIC POLYMORPHISMS OF CYP2C19 IN POST-PARTUM WOMEN OF ASIAN, NATIVE HAWAIIAN, AND PACIFIC ISLANDER SUBGROUPS: IMPLICATIONS FOR PERSONALIZED MEDICINE.

P-016 - PEDIATRIC CYP2D6 METABOLIZER STATUS AND POST-TONSILLECTOMY NAUSEA AND VOMITING AFTER ONDANSETRON ADMINISTRATION.

P-020 - POPULATION PHARMACOKINETICS OF ATOMOXETINE AND ITS METABOLITES IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD).

P-021 - PHARMACOGENETICS IN PEDIATRIC PSYCHIATRY: CONSIDERATIONS FOR IMPLEMENTATION IN RURAL COMMUNITIES.

P-023 - FUNCTIONAL GENOMICS OF RARE CODING VARIANTS IN THE GABA TRANSPORTER, GAT-1 (SLC6A1).

P-060 - ADRA2A GENOTYPE IS NOT A PREDICTOR OF DEXMEDETOMIDINE DOSE IN CRITICALLY ILL PEDIATRIC PATIENTS.

P-085 - INCREASED TACROLIMUS EXPOSURE IN KIDNEY TRANSPLANT RECIPIENTS WITH COVID-19: INFLAMMATION-DRIVEN INHIBITION OF METABOLISM AS A POTENTIAL MECHANISM.

P-088 - ADDITION OF PHARMACOGENE VARIANTS TO CLINICAL RISK FACTORS (e.g. HAS-BLED SCORE) IMPROVES BLEEDING RISK PREDICTION FOR PATIENTS ON RIVAROXABAN.

P-094 - UTILIZATION OF PHARMACOGENOMIC INFORMATION IN BIOEQUIVALENCE STUDIES FOR GENERIC DRUG DEVELOPMENT.

P-122 - IMPACT OF CYP3A4, CYP3A5, AND ABCB1 ON ORAL TACROLIMUS (TAC) CONCENTRATIONS WHEN TRANSITIONING FROM CONTINUOUS INFUSION INTRAVENOUS (IV) TO ORAL FORMULATION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT) RECIPIENTS.

P-124 - PREVALENCE OF CLINICALLY ACTIONABLE CYP2C19 AND CYP2D6 PHENOTYPES AND ANTIDEPRESSANTS WITH PHARMACOGENOMIC (PGX) INFORMATION PRESCRIBED AT THE UNIVERSITY OF CHICAGO.

P-125 - COLLABORATIVE APPROACH AMONG PHARMACISTS, PHYSICIANS, AND GENETICS TEAM TO ADDRESS KLINEFELTER SYNDROME INCIDENTAL FINDINGS DISCOVERED BY PHARMACOGENOMIC TESTING.

P-131 - EXPLORATORY PHARMACOGENETIC STUDY IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS RECEIVING CYP2C19-GUIDED VORICONAZOLE (VCZ) DOSING.

P-133 - GENOTYPE AND PHENOTYPE FREQUENCIES OF TPMT AND NUDT15 IN PEDIATRIC PATIENTS MEASURED BY SANGER SEQUENCING.

P-137 - PHARMACOGENETIC INFLUENCE OF CYP2C19 VARIATION ON ESCITALOPRAM PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS.

P-140 - PHARMACOGENETICALLY-GUIDED ESCITALOPRAM TREATMENT FOR PEDIATRIC ANXIETY: AIMING TO IMPROVE SAFETY AND EFFICACY (PRECISE).

P-144 - ARIPIPRAZOLE, CYTOCHROME P450 2D6, AUTISM SPECTRUM DISORDER, AND ADVERSE EVENTS IN CHILDREN AND ADOLESCENTS.

P-145 - PHARMACOGENOMICS IMPLEMENTATION IN THE INDIANA UNIVERSITY PRECISION HEALTH INITIATIVE: A QUALITATIVE EVALUATION.

P-158 - SEVERE SUNITINIB- AND AXITINIB-INDUCED CARDIOMYOPATHY IN A PATIENT WITH GENETIC VARIANTS ASSOCIATED WITH FAMILIAL CARDIOMYOPATHY AND REDUCED CYP3A FUNCTION.

P-165 - COMPARISON OF POST-OPERATIVE (POST-OP) OPIOID PAIN MANAGEMENT OUTCOMES BY CYP2D6 GENOTYPE.

P-172 - INFLUENCE OF CYP2D6 GENETIC VARIATION ON ADVERSE EVENTS WITH PROPAFENONE IN THE PEDIATRIC AND YOUNG ADULT POPULATION.

P-178 - GENETIC ASSOCIATION OF URIC ACID CHANGE AFTER THIAZIDE/THIAZIDE-LIKE DIURETIC TREATMENT – ANALYSIS OF THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDIES.

P-184 - A TARGETED LONG-READ SEQUENCING APPROACH FOR PHARMACOGENOMICS.

P-185 - CYP2C19 METABOLIZER PHENOTYPE INFLUENCES SERTRALINE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS.

P-192 - THE FUNCTIONAL IMPORTANCE OF CYP2C9*11.

PT-005 - IDENTIFICATION OF A DISTAL ENHANCER AND REGULATORY VARIANTS CONTROLLING EXPRESSION OF THE CYP3A GENES.

PT-005 - IDENTIFICATION OF A DISTAL ENHANCER AND REGULATORY VARIANTS CONTROLLING EXPRESSION OF THE CYP3A GENES.

PT-008 - PHARMACOGENOMIC GENOME-WIDE META-ANALYSIS TO IDENTIFY VARIANTS ASSOCIATED WITH THIAZIDE AND THIAZIDE-LIKE DIURETIC INDUCED GLUCOSE CHANGE.

PT-008 - PHARMACOGENOMIC GENOME-WIDE META-ANALYSIS TO IDENTIFY VARIANTS ASSOCIATED WITH THIAZIDE AND THIAZIDE-LIKE DIURETIC INDUCED GLUCOSE CHANGE.

PT-011 - INVESTIGATION OF CARDIOVASCULAR OUTCOMES IN BLACK PATIENTS FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD CLINICAL SETTING.

PT-011 - INVESTIGATION OF CARDIOVASCULAR OUTCOMES IN BLACK PATIENTS FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD CLINICAL SETTING.

PT-013 - CORTISOL REGULATES ALTERNATIVE POLYADENYLATION IN A GENOTYPE-DEPENDENT MANNER: GLUCOCORTICOID-DEPENDENT PHARMACOGENOMIC ALTERNATIVE POLYADENYLATION QUANTITATIVE TRAIT LOCI (PGx-3’aQTLs).

PT-013 - CORTISOL REGULATES ALTERNATIVE POLYADENYLATION IN A GENOTYPE-DEPENDENT MANNER: GLUCOCORTICOID-DEPENDENT PHARMACOGENOMIC ALTERNATIVE POLYADENYLATION QUANTITATIVE TRAIT LOCI (PGx-3’aQTLs).

PT-014 - RISK STRATIFICATION WITH PRE-TREATMENT METABOLITE RISK SCORE FOR CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS.

PT-014 - RISK STRATIFICATION WITH PRE-TREATMENT METABOLITE RISK SCORE FOR CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS.

PT-018 - A POLYGENIC DNA DAMAGE REPAIR PHARMACOGENOMICS (DDR_PGX) SCORE PREDICTS RESPONSE TO GEMTUZUMAB OZOGAMICIN IN PEDIATRIC AML PATIENTS.

PT-018 - A POLYGENIC DNA DAMAGE REPAIR PHARMACOGENOMICS (DDR_PGX) SCORE PREDICTS RESPONSE TO GEMTUZUMAB OZOGAMICIN IN PEDIATRIC AML PATIENTS.

PT-020 - IMPACT OF CYP2C19 GENOTYPE ON PREDICTION OF CARDIOVASCULAR EVENTS WITH THE ABCD-GENE SCORE AMONG PATIENTS RECEIVING CYP2C19-GUIDED ANTIPLATELET THERAPY AFTER PCI.

PT-020 - IMPACT OF CYP2C19 GENOTYPE ON PREDICTION OF CARDIOVASCULAR EVENTS WITH THE ABCD-GENE SCORE AMONG PATIENTS RECEIVING CYP2C19-GUIDED ANTIPLATELET THERAPY AFTER PCI.

PW-001 - METABOLOMICS-INFORMED-PHARMACOGENOMIC-BASED PREDICTIONS OF RESPONSE TO COMBINATION ANTIDEPRESSANT THERAPIES: A MACHINE LEARNING APPROACH WITH CROSS-TRIAL REPLICATION.

PW-002 - ASSESSMENT OF A PHARMACIST-PROVIDED PHARMACOGENOMICS SERVICE IN A CONCIERGE MEDICINE PRACTICE MODEL.

PW-003 - COST EFFECTIVENESS (CE) OF PHARMACOGENETIC (PGX) TESTING FOR DRUGS WITH CLINICAL PHARMACOGENETICS IMPLEMENTATION CONSORTIUM (CPIC) GUIDELINES: A SYSTEMATIC REVIEW.

PW-004 - TMSB10/TRABD2A LOCUS ASSOCIATED WITH CARFILZOMIB RELATED CARDIOTOXICITY IN PATIENTS WITH MULTIPLE MYELOMA: AN WHOLE-EXOME SEQUENCING ANALYSIS.

PW-010 - NOVEL GENOMIC MARKERS OF BLOOD PRESSURE RESPONSE TO THIAZIDE DIURETICS IN HYPERTENSIVE AFRICAN AMERICANS: FINDINGS USING THE LATEST TOPMED IMPUTATION PANEL.

PW-011 - REPORTED RACE, ACKR1 VARIATION, AND RISK FOR DISCONTINUATION OF AZATHIOPRINE ATTRIBUTED TO HEMATOPOIETIC TOXICITY IN PATIENTS TREATED FOR INFLAMMATORY DISORDERS.

PW-020 - EVALUATING THE IMPACT OF THE ABCD-GENE SCORE ON ANTIPLATELET THERAPY OUTCOMES FOLLOWING PERCUTANEOUS CORONARY INTERVENTION IN A REAL-WORLD CLINICAL SETTING.